FDA Approved Orzeyful, Replacing What Narcolepsy Type 1 Patients Lack
The August 5, 2026 approval of oveporexton brings the first orexin receptor agonist to market — wakefulness restored, not stimulated. What patients should ask.
Written by Grace Mensah
